K
K Govind Babu
Researcher at Kidwai Memorial Institute of Oncology
Publications - 97
Citations - 1837
K Govind Babu is an academic researcher from Kidwai Memorial Institute of Oncology. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 16, co-authored 92 publications receiving 1343 citations. Previous affiliations of K Govind Babu include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy,Seock-Ah Im,Marco Colleoni,Fabio Franke,Aditya Bardia,Nadia Harbeck,Sara A. Hurvitz,Louis W.C. Chow,Joohyuk Sohn,Keun Seok Lee,Saúl Campos-Gómez,Rafael Villanueva Vazquez,Kyung Hae Jung,K Govind Babu,Paul Wheatley-Price,Michelino De Laurentiis,Young-Hyuck Im,Sherko Kuemmel,Nagi S. El-Saghir,Mei Ching Liu,Gary Carlson,Gareth Hughes,I Diaz-Padilla,C. Germa,Samit Hirawat,Yen-Shen Lu +25 more
TL;DR: In this paper, ribociclib plus endocrine therapy showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer.
Journal ArticleDOI
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen,Tadeusz Robak,Ann Janssens,K Govind Babu,Janusz Kloczko,Sebastian Grosicki,Michael Doubek,Panagiotis Panagiotidis,Eva Kimby,Anna Schuh,Andrew R. Pettitt,Thomas E. Boyd,Marco Montillo,Ira Gupta,Oliver Wright,Iestyn Dixon,Jodi L Carey,Chai-Ni Chang,Steen Lisby,Astrid McKeown,Fritz Offner +20 more
TL;DR: Addition of ofatumumab to chlorambucil led to clinically important improvements with a manageable side-effect profile in treatment-naive patients with chronic lymphocytic leukaemia who were elderly or had comorbidities.
Journal ArticleDOI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Kwang Bo Park,Johan Vansteenkiste,Ki Hyeong Lee,Georgios Pentheroudakis,C. Zhou,Kumar Prabhash,Takashi Seto,P.J. Voon,D.S.W. Tan,J.C.-H. Yang,Jinwan Wang,K Govind Babu,Y. Nakayama,Adlinda Alip,K.L.M. Chua,Jason Chia-Hsien Cheng,Suresh Senan,Yong Chan Ahn,Tae Yong Kim,Hee Kyung Ahn,Solange Peters,Takayuki Yoshino,J.-Y. Douillard +22 more
TL;DR: These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS).
Journal ArticleDOI
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
Tadeusz Robak,Krzysztof Warzocha,K Govind Babu,Yaroslav Kulyaba,Kazimierz Kuliczkowski,Kudrat Abdulkadyrov,Javier Loscertales,Iryna Kryachok,Janusz Kloczko,Grygoriy Rekhtman,Wojciech Homenda,Jerzy Z. Blonski,Astrid McKeown,Michele Gorczyca,Jodi L Carey,Chai-Ni Chang,Steen Lisby,Ira Gupta,Sebastian Grosicki +18 more
TL;DR: OFA + FC improved PFS with manageable safety for patients with relapsed CLL compared with FC alone, thus providing an alternative treatment option for patientsWith relapsed chronic lymphocytic leukemia.
Journal ArticleDOI
Cancer-associated thrombotic microangiopathy.
K Govind Babu,Gita R Bhat +1 more
TL;DR: Careful review of the patient’s medical records coupled with the correlation of clinical findings and laboratory reports can help clinch the diagnosis and institute appropriate treatment on time.